Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$1.16 | -$0.91 | -$1.04 |
Q2 2025 | 1 | -$1.08 | -$1.08 | -$1.08 |
Q3 2025 | 1 | -$1.14 | -$1.14 | -$1.14 |
Q4 2025 | 1 | -$1.22 | -$1.22 | -$1.22 |
Q1 2026 | 1 | -$1.20 | -$1.20 | -$1.20 |
Q2 2026 | 1 | -$1.25 | -$1.25 | -$1.25 |
Q3 2026 | 1 | -$1.25 | -$1.25 | -$1.25 |
Q4 2026 | 1 | -$1.35 | -$1.35 | -$1.35 |
Vaxcyte, Inc. last posted its earnings results on Tuesday, February 25th, 2025. The company reported $-1.02 earnings per share for the quarter, topping analysts' consensus estimates of $-1.16 by $0.14. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Vaxcyte, Inc. has generated $-4 earnings per share over the last year ($-3.8 diluted earnings per share) and currently has a price-to-earnings ratio of -19.39. Vaxcyte, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
02/25/2025 | Q4 2024 | -$1.16 | -$1.12 | 0.04 | $0 | $0 |
11/05/2024 | Q3 2024 | -$1.10 | -$0.83 | 0.27 | $0 | $0 |
08/06/2024 | Q2 2024 | -$0.98 | -$1.10 | -0.12 | $0 | $0 |
05/08/2024 | Q1 2024 | -$1.13 | -$0.85 | 0.28 | N/A | $0 |
02/27/2024 | Q4 2023 | -$0.90 | -$1.76 | -0.86 | N/A | $14.45 M |
11/06/2023 | Q3 2023 | -$0.79 | -$0.91 | -0.12 | N/A | $0 |
08/08/2023 | Q2 2023 | -$0.67 | -$0.70 | -0.03 | N/A | $0 |
05/08/2023 | Q1 2023 | -$0.80 | -$0.56 | 0.24 | N/A | $0 |
02/27/2023 | Q4 2022 | -$0.84 | -$1.18 | -0.34 | N/A | $0 |
11/07/2022 | Q3 2022 | -$0.80 | -$0.92 | -0.12 | N/A | $0 |
08/08/2022 | Q2 2022 | -$0.69 | -$0.81 | -0.12 | N/A | $0 |
05/09/2022 | Q1 2022 | -$0.56 | -$0.68 | -0.12 | N/A | $0 |
02/28/2022 | Q4 2021 | -$0.46 | -$0.54 | -0.08 | N/A | $0 |
11/10/2021 | Q3 2021 | -$0.47 | -$0.51 | -0.04 | N/A | $0 |
08/11/2021 | Q2 2021 | -$0.46 | -$0.46 | 0 | N/A | $0 |
05/11/2021 | Q1 2021 | -$0.41 | -$0.41 | 0 | N/A | $0 |
03/29/2021 | Q4 2020 | -$0.48 | -$0.41 | 0.07 | N/A | $0 |
11/12/2020 | Q3 2020 | -$0.42 | -$1.02 | -0.6 | N/A | $0 |
08/12/2020 | Q2 2020 | -$1.27 | -$1.72 | -0.45 | $166,667 | $0 |
03/30/2020 | Q1 2020 | N/A | -$6.70 | N/A | N/A | $0 |
Vaxcyte, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based offlast year's report dates.
In the previous quarter, Vaxcyte, Inc. (:PCVX) reported $-1.02 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.16 by $0.14.
The conference call for Vaxcyte, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Vaxcyte, Inc.'s latest earnings report can be read online.
Vaxcyte, Inc. (:PCVX) has a recorded net income of $-463,927,000.Vaxcyte, Inc. has generated $-3.8 earnings per share over the last four quarters.
Vaxcyte, Inc. (:PCVX) has a price-to-earnings ratio of -19.39 and price/earnings-to-growth ratio is -1.38.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED